Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Blood

Retrieve available abstracts of 374 articles:
HTML format

Single Articles

    November 2021
    MLL-AF4+ infant leukemia: a microRNA affair.
    Blood. 2021;138:2014-2015.

  2. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available

  3. ZHONG W, Cao X, Pan G, Niu Q, et al
    ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
    Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
    PubMed     Abstract available

  4. GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
    PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
    Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
    PubMed     Abstract available

  5. ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
    MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
    Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
    PubMed     Abstract available

  6. LANGERBEINS P, Zhang C, Robrecht S, Cramer P, et al
    The CLL12 trial: Ibrutinib versus placebo in treatment-naive, early stage chronic lymphocytic leukemia.
    Blood. 2021 Nov 10. pii: 477942. doi: 10.1182/blood.2021010845.
    PubMed     Abstract available

  7. HASLE H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, et al
    Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Blood. 2021 Nov 10. pii: 477943. doi: 10.1182/blood.2021011463.
    PubMed     Abstract available

  8. FENG Y, Feng W
    Numerous ring sideroblasts in chronic neutrophilic leukemia.
    Blood. 2021;138:1783.

  9. HERISHANU Y, Perry C
    COVID-19 in patients with CLL: how can we change the odds?
    Blood. 2021;138:1652-1653.

  10. ROEKER LE, Eyre TA, Thompson MC, Lamanna N, et al
    COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
    Blood. 2021;138:1768-1773.

  11. HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
    2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
    Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
    PubMed     Abstract available

    October 2021
  12. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available

  13. SCHNOEDER TM, Schwarzer A, Jayavelu AK, Hsu CJ, et al
    PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01783-3. doi: 10.1182/blood.2021012778.
    PubMed     Abstract available

  14. YASUDA T, Sanada M, Kawazu M, Kojima S, et al
    Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01785-7. doi: 10.1182/blood.2021011921.
    PubMed     Abstract available

  15. ZHAO Y, Wang E
    Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.
    Blood. 2021;138:1510.

  16. JEBARAJ BMC, Muller A, Dheenadayalan RP, Endres S, et al
    Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
    Blood. 2021 Oct 18. pii: 477372. doi: 10.1182/blood.2021011516.
    PubMed     Abstract available

  17. KOLIJN PMM, Saberi Hosnijeh F, Spath F, Hengeveld PJ, et al
    Blood. 2021 Oct 18. pii: 477373. doi: 10.1182/blood.2021012890.
    PubMed     Abstract available

  18. FISHMAN H, Madiwale S, Geron I, Bari V, et al
    ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
    Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
    PubMed     Abstract available

  19. PROSSER AL, Li W
    Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
    Blood. 2021;138:1282.

    September 2021
  20. SIERRA J, Nomdedeu JF
    CEBPA bZip mutations: just a single shot.
    Blood. 2021;138:1091-1092.

  21. ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
    The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
    Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
    PubMed     Abstract available

    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.

  23. HAN C, Ntziachristos P
    T-ALL and the talented Mr IL7Ralpha.
    Blood. 2021;138:1003-1004.

  24. DEANGELO DJ, Jonas BA, Liesveld JL, Bixby DL, et al
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
    Blood. 2021 Sep 20. pii: 476977. doi: 10.1182/blood.2021010721.
    PubMed     Abstract available

  25. BERMAN E
    How I Treat Chronic Phase Chronic Myelogenous Leukemia.
    Blood. 2021 Sep 16. pii: 476939. doi: 10.1182/blood.2021011722.
    PubMed     Abstract available

  26. AMAYA M, Inguva A, Pei S, Jones CL, et al
    The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation.
    Blood. 2021 Sep 15. pii: 476917. doi: 10.1182/blood.2021013201.
    PubMed     Abstract available

  27. SAMARAWEERA SE, Wang PP, Li KL, Casolari DA, et al
    Childhood Acute Myeloid Leukemia shows a high level of germline predisposition.
    Blood. 2021 Sep 14. pii: 476894. doi: 10.1182/blood.2021012666.

  28. ROSSOFF J, Baggott C, Prabhu S, Pacenta HL, et al
    Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
    Blood. 2021 Sep 9. pii: 476839. doi: 10.1182/blood.2021012392.

  29. DAVIS AG, Johnson DT, Zheng D, Wang R, et al
    Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia.
    Blood. 2021 Sep 5. pii: 476791. doi: 10.1182/blood.2020005693.
    PubMed     Abstract available

    BCL11B, the Cerberus of human leukemia.
    Blood. 2021;138:741-743.

  31. SILVA O, Kurzer J
    Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations.
    Blood. 2021;138:818.

    August 2021
  32. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.

  33. WHEAT JC, Steidl U
    Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2021;138:625-636.
    PubMed     Abstract available

  34. MESSLING JE, Agger K, Andersen KL, Kromer K, et al
    Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
    Blood. 2021 Aug 25. pii: 476529. doi: 10.1182/blood.2021012629.
    PubMed     Abstract available

  35. ASTOLFI A, Masetti R, Indio V, Bertuccio SN, et al
    Torque Teno Mini Virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
    Blood. 2021 Aug 25. pii: 476664. doi: 10.1182/blood.2021011677.

  36. ZANETTI C, Kumar R, Ender J, Godavarthy PS, et al
    The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
    Blood. 2021 Aug 23. pii: 476652. doi: 10.1182/blood.2021011557.
    PubMed     Abstract available

    AML onco-niche: villain or ally?
    Blood. 2021;138:504-506.

    CLL cells are moved by the MARCKS brothers.
    Blood. 2021;138:503-504.

    A slow-go prognosis for older patients with newly diagnosed AML.
    Blood. 2021;138:501-502.

  40. CORTES J, Apperley JF, Lomaia E, Moiraghi B, et al
    Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
    Blood. 2021 Aug 18. pii: 476603. doi: 10.1182/blood.2021012082.
    PubMed     Abstract available

  41. ALVES DA SILVA PH, Xing S, Kotini AG, Papapetrou EP, et al
    MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
    Blood. 2021 Aug 6. pii: 476528. doi: 10.1182/blood.2021011619.
    PubMed     Abstract available

  42. SORROR ML, Storer BE, Fathi AT, Brunner A, et al
    Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
    Blood. 2021;138:387-400.
    PubMed     Abstract available

    July 2021
  43. HALSEY C, Escherich G
    A "Goldilocks" approach to CNS leukemia is needed.
    Blood. 2021;138:288-289.

  44. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Blood. 2021;138:318-330.
    PubMed     Abstract available

  45. TAUBE F, Georgi JA, Kramer M, Stasik S, et al
    CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.
    Blood. 2021 Jul 28. pii: 476465. doi: 10.1182/blood.2020009680.
    PubMed     Abstract available

  46. PUZZOLO MC, Radice G, Peragine N, de Propris MS, et al
    Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Blood. 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.

  47. GOOPTU M, Romee R, St Martin A, Arora M, et al
    HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Blood. 2021;138:273-282.
    PubMed     Abstract available

  48. LEE JB, Khan DH, Hurren R, Xu M, et al
    Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
    Blood. 2021;138:234-245.
    PubMed     Abstract available

  49. MORANDE PE, Yan XJ, Sepulveda J, Seija N, et al
    AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
    Blood. 2021;138:246-258.
    PubMed     Abstract available

  50. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    PubMed     Abstract available

  51. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    PubMed     Abstract available

  52. KUTSCH N
    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.

  53. PARIKH SA, Rabe KG, Kay NE, Call TG, et al
    The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
    Blood. 2021;138:149-159.
    PubMed     Abstract available

  54. MULET-LAZARO R, van Herk S, Erpelinck C, Bindels E, et al
    Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Blood. 2021;138:160-177.
    PubMed     Abstract available

  55. ZHENG W, Wei J, Zebley CC, Jones LL, et al
    Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Blood. 2021;138:122-135.
    PubMed     Abstract available

  56. KRANC KR
    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.

  57. LINLEY AJ, Slupsky JR
    Poor prognosis is ZAP70'ed into focus in CLL.
    Blood. 2021;137:3586-3587.

    June 2021
  58. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    PubMed     Abstract available

  59. TABE Y, Konopleva M
    Break the lifeline of AML cells.
    Blood. 2021;137:3465-3467.

  60. MORENO C
    Autoimmune cytopenia and CLL ride together.
    Blood. 2021;137:3464-3465.

    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.

  62. SMOLEJ L
    On the road to optimized BTK inhibition in CLL.
    Blood. 2021;137:3313-3314.

  63. LOKE J, Cockerill PN
    Unravelling the apoptotic machinery in CMML.
    Blood. 2021;137:3321-3322.

  64. KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
    Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
    Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
    PubMed     Abstract available

  65. RUBNITZ JE, Kaspers GJL
    How I treat pediatric acute myeloid leukemia.
    Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
    PubMed     Abstract available

  66. LV K, Ren JG, Han X, Gui J, et al
    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
    Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
    PubMed     Abstract available

  67. MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
    MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
    Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
    PubMed     Abstract available

  68. CHANG Y, Min J, Jarusiewicz J, Actis M, et al
    Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
    PubMed     Abstract available

    Vaccination against COVID-19: a challenge in CLL.
    Blood. 2021;137:3153-3154.

    Checkpoint-blocked T cells checkmate AML.
    Blood. 2021;137:3155-3156.

  71. HERLING M, Braun T
    Tracing the roots of CLPD-NK by TET2 and STAT3.
    Blood. 2021;137:3156-3158.

  72. BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
    MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
    Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
    PubMed     Abstract available

  73. JONES RJ, DeBaun MR
    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
    Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
    PubMed     Abstract available

  74. TANAKA T, Morita K, Wang F, Loghavi S, et al
    Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
    PubMed     Abstract available

    Revisiting TLR9 as a target for CLL therapy.
    Blood. 2021;137:3006-3008.

  76. DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
    Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
    Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
    PubMed     Abstract available

  77. AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
    Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
    Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
    PubMed     Abstract available

  78. STEVENSON FK, Forconi F, Kipps TJ
    Exploring the Pathways to Chronic Lymphocytic Leukemia.
    Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
    PubMed     Abstract available

    May 2021
  79. GHIA P, Stamatopoulos K
    In CLL, epigenetics also points to the BCR.
    Blood. 2021;137:2863-2865.

  80. FOWLER N
    Kinase inhibitors in CLL: drawing the roadmap.
    Blood. 2021;137:2717-2719.

  81. GANSER A
    What can Heraclitus tell us about AML?
    Blood. 2021;137:2719-2720.

  82. BORELLA G, Da Ros A, Borile G, Porcu E, et al
    Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
    Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
    PubMed     Abstract available

  83. VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
    Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
    Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
    PubMed     Abstract available

  84. ESCRIBANO SERRAT S, Calo Perez A
    Pure erythroid leukemia.
    Blood. 2021;137:2709.

  85. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  86. WIMMER J, Hurstel R
    Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Blood. 2021;137:2564.

  87. PADI SKR, Kraft AS
    "Root"ing for successful T-ALL treatment.
    Blood. 2021;137:2422-2423.

    April 2021
  88. ANDRIEU GP, Asnafi V
    Integrated omics approaches to predict T-LBL relapse risk.
    Blood. 2021;137:2280-2282.

  89. SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
    Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
    PubMed     Abstract available

  90. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.

    IL-9 in CLL: sensing home and settling down!
    Blood. 2021;137:2130-2131.

  92. SOARES F, Chen B, Lee JB, Ahmed M, et al
    CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
    Blood. 2021;137:2171-2181.
    PubMed     Abstract available

  93. DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
    A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
    Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
    PubMed     Abstract available

  94. MITTELMAN SD, Kim J, Raca G, Li G, et al
    Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
    Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.

  95. LEW TE, Tam CS, Seymour JF
    How I treat chronic lymphocytic leukemia after venetoclax.
    Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
    PubMed     Abstract available

  96. DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
    14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
    Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
    PubMed     Abstract available

  97. HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
    Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
    Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
    PubMed     Abstract available

  98. AMES E, Silva O
    Polytypic T-cell prolymphocytic leukemia.
    Blood. 2021;137:2125.

  99. SANDBERG Y, Weerkamp F
    Charcot-Leyden crystals in chronic eosinophilic leukemia.
    Blood. 2021;137:1985.

  100. SEFTEL MD
    Has MRD graduated from its adolescence in ALL?
    Blood. 2021;137:1846-1847.

  101. KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
    A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Blood. 2021;137:1970-1979.
    PubMed     Abstract available

  102. GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
    Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
    Blood. 2021;137:1895-1904.
    PubMed     Abstract available

  103. SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
    KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
    Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
    PubMed     Abstract available

  104. WEI AH, Daver N
    Taking aim at IDH in fitter patients with AML.
    Blood. 2021;137:1706-1707.

  105. SCHWAB C, Roberts K, Boer JM, Gohring G, et al
    SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
    Blood. 2021;137:1835-1838.

  106. STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
    Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood. 2021;137:1792-1803.
    PubMed     Abstract available

    March 2021
  107. BYRD JC, Woyach JA, Furman RR, Martin P, et al
    Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475651. doi: 10.1182/blood.2020009617.
    PubMed     Abstract available

  108. NIU X, Rothe K, Chen M, Grasedieck S, et al
    Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia.
    Blood. 2021 Mar 30. pii: 475648. doi: 10.1182/blood.2020007651.
    PubMed     Abstract available

  109. OLSON TL, Cheon H, Xing JC, Olson KC, et al
    Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.
    Blood. 2021 Mar 30. pii: 475646. doi: 10.1182/blood.2020005831.
    PubMed     Abstract available

  110. SEDA V, Vojackova E, Ondrisova L, Kostalova L, et al
    FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475649. doi: 10.1182/blood.2020008101.
    PubMed     Abstract available

  111. ZHANG JP, Cheng T
    Modeling acute erythroid leukemia via CRISPR.
    Blood. 2021;137:1565-1567.

  112. CHANG H, Eladl E
    Multiple Auer rods in a mixed-phenotype acute leukemia.
    Blood. 2021;137:1702.

  113. JABBOUR E, Kantarjian H
    A new era in the treatment of acute lymphoblastic leukemia.
    Blood. 2021;137:1563-1564.

  114. IACOBUCCI I, Qu C, Varotto E, Janke LJ, et al
    Modeling and targeting of erythroleukemia by hematopoietic genome editing.
    Blood. 2021;137:1628-1640.
    PubMed     Abstract available

  115. SIMONIN M, Lhermitte L, Dourthe ME, Lengline E, et al
    IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
    Blood. 2021;137:1690-1694.

  116. FENG M, Xie X, Han G, Zhang T, et al
    YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.
    Blood. 2021 Mar 24. pii: 475592. doi: 10.1182/blood.2020009676.
    PubMed     Abstract available

  117. ROGERS KA, Andritsos LA, Wei L, McLaughlin E, et al
    Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
    Blood. 2021 Mar 22. pii: 475585. doi: 10.1182/blood.2020009688.
    PubMed     Abstract available

  118. RASLAN O, Hsia CC
    Cabot rings in acute myeloid leukemia.
    Blood. 2021;137:1560.

  119. KOGAN SC
    PML-RARalpha: changing myeloid networks.
    Blood. 2021;137:1439-1440.

  120. TCHENG M, Roma A, Ahmed N, Smith RW, et al
    Very long chain fatty acid metabolism is required in acute myeloid leukemia.
    Blood. 2021 Mar 15. pii: 475526. doi: 10.1182/blood.2020008551.
    PubMed     Abstract available

  121. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.
    Blood. 2021 Mar 15. pii: 475523. doi: 10.1182/blood.2020008221.
    PubMed     Abstract available

  122. ERNST MPT, Kavelaars FG, Lowenberg B, Valk PJM, et al
    RUNX1 germline variants in RUNX1-mutant AML: how frequent?
    Blood. 2021;137:1428-1431.

  123. AGATHANGELIDIS A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, et al
    Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
    Blood. 2021;137:1365-1376.
    PubMed     Abstract available

  124. MURALI I, Kasar S, Naeem A, Tyekucheva S, et al
    Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).
    Blood. 2021 Mar 8. pii: 475459. doi: 10.1182/blood.2020006765.
    PubMed     Abstract available

  125. TANG J, Yu J, Cai J, Zhang L, et al
    Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
    Blood. 2021 Mar 8. pii: 475463. doi: 10.1182/blood.2020010438.
    PubMed     Abstract available

  126. NAZHA A
    Should I rock the boat? When to stop TKIs in CML.
    Blood. 2021;137:1136-1137.

    February 2021
    CAR-T treatment of pediatric AML: a long and winding road.
    Blood. 2021;137:1004-1006.

  128. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    PubMed     Abstract available

  129. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    PubMed     Abstract available

  130. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    PubMed     Abstract available

  131. CHEN J, Sathiaseelan V, Moore AD, Tan S, et al
    ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
    Blood. 2021 Feb 22. pii: 475287. doi: 10.1182/blood.2020009960.
    PubMed     Abstract available

  132. Pediatric disease risk index for acute leukemia.
    Blood. 2021;137:1001.

  133. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    PubMed     Abstract available

  134. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    PubMed     Abstract available

  135. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    PubMed     Abstract available

  136. SCHMALBROCK LK, Dolnik A, Cocciardi S, Strang E, et al
    Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Blood. 2021 Feb 17. pii: 475246. doi: 10.1182/blood.2020007626.
    PubMed     Abstract available

  137. HERBAUX C, Kornauth C, Poulain S, Chong SJF, et al
    BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Blood. 2021 Feb 17. pii: 475244. doi: 10.1182/blood.2020007303.
    PubMed     Abstract available

  138. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.

  139. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.

  140. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.

  141. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  142. GRANT S
    Targeting cereblon in AML.
    Blood. 2021;137:584-586.

  143. BROWN JR
    AKT: a key to RT?
    Blood. 2021;137:582-584.

  144. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  145. FALINI B, Brunetti L, Martelli MP
    How I diagnose and treat NPM1-mutated AML.
    Blood. 2021;137:589-599.
    PubMed     Abstract available

    January 2021
  146. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.
    Blood. 2021;137:569-572.

  147. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2021;137:500-512.
    PubMed     Abstract available

  148. SHOUVAL R, Soiffer RJ
    Primum non nocere: allo-HSCT for AML in CR1.
    Blood. 2021;137:438-439.

  149. COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
    High frequency of clonal hematopoiesis in Erdheim-Chester disease.
    Blood. 2021;137:485-492.
    PubMed     Abstract available

  150. ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
    Blood. 2021;137:471-484.
    PubMed     Abstract available

  151. SONG Q, Wang X, Wu X, Qin H, et al
    Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Blood. 2021 Jan 27. pii: 475053. doi: 10.1182/blood.2020006345.
    PubMed     Abstract available

  152. RIO-MACHIN A, Fitzgibbon J
    Germline ETV6 variants: not ALL created equally.
    Blood. 2021;137:288-289.

  153. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  154. WEN Z, Yun G, Hebert A, Kong G, et al
    NrasQ61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Blood. 2021 Jan 19. pii: 475000. doi: 10.1182/blood.2020009082.
    PubMed     Abstract available

  155. SHADMAN M, Ujjani C
    Vaccinations in CLL: implications for COVID-19.
    Blood. 2021;137:144-146.

  156. MERTENS D, Kronke J
    Triggering T-cell activity in CLL.
    Blood. 2021;137:150-151.

  157. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.

  158. AL MOOSAWI M, Vercauteren S
    Cerebrospinal fluid with unusual natural killer cell population.
    Blood. 2021;137:281.

  159. IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
    Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Blood. 2021;137:216-231.
    PubMed     Abstract available

  160. SALIB C, Hussein S
    A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
    Blood. 2021;137:142.

  161. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
    Blood. 2021;137:20-28.
    PubMed     Abstract available

  162. KENNEDY E, Coulter EM, Halliwell E, Profitos-Peleja N, et al
    TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.
    Blood. 2021 Jan 7. pii: 474915. doi: 10.1182/blood.2020005964.
    PubMed     Abstract available

  163. CORRE J
    Undetectable MRD can change the deal.
    Blood. 2021;137:5-6.

  164. KEESHAN K
    Superenhancing AML with Trib1.
    Blood. 2021;137:8-9.

    December 2020
  165. MATTERN S, Nann D
    Small lymphocytic leukemia with herpes simplex virus infection simulating metastatic cancer.
    Blood. 2020;136:3087.

  166. KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
    Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Blood. 2020;136:3041-3050.
    PubMed     Abstract available

  167. FURSTENAU M, Fink AM, Schilhabel A, Weiss J, et al
    B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.
    Blood. 2020 Dec 23. pii: 474779. doi: 10.1182/blood.2020008609.
    PubMed     Abstract available

  168. FAZIO G, Bardini M, de Lorenzo P, Grioni A, et al
    Blood. 2020 Dec 22. pii: 474771. doi: 10.1182/blood.2020009032.

  169. SLAGER SL, Lanasa MC, Marti GE, Achenbach SJ, et al
    Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families.
    Blood. 2020 Dec 21. pii: 474760. doi: 10.1182/blood.2020006322.
    PubMed     Abstract available

  170. TARDIVON D, Antoszewski M, Zangger N, Nkosi M, et al
    Notch Signaling Promotes Disease Initiation and Progression in Murine Chronic Lymphocytic Leukemia.
    Blood. 2020 Dec 18. pii: 474750. doi: 10.1182/blood.2020006701.
    PubMed     Abstract available

  171. MIAO H, Kim E, Chen D, Purohit T, et al
    Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Blood. 2020;136:2958-2963.

  172. LIU Y, Panetta JC, Yang W, Karol SE, et al
    Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
    Blood. 2020;136:2955-2958.

  173. HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
    Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood. 2020;136:2918-2926.
    PubMed     Abstract available

  174. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.
    Blood. 2020;136:2764-2773.
    PubMed     Abstract available

  175. PLATZBECKER U, Kordasti S
    Natural born survivors: the inglorious TP53.
    Blood. 2020;136:2727-2728.

  176. OBERBECK S, Schrader A, Warner K, Jungherz D, et al
    Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Blood. 2020;136:2786-2802.
    PubMed     Abstract available

  177. SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
    TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Blood. 2020;136:2812-2823.
    PubMed     Abstract available

  178. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    PubMed     Abstract available

  179. TASHAKORI M, Khoury JD
    B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.
    Blood. 2020;136:2720.

  180. LULLA P, Naik S, Vasileiou S, Tzannou I, et al
    Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.
    Blood. 2020 Dec 3. pii: 474389. doi: 10.1182/blood.2020009471.
    PubMed     Abstract available

  181. PLEYER C, Ali MA, Cohen JI, Tian X, et al
    Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Blood. 2020 Dec 1. pii: 474376. doi: 10.1182/blood.2020008758.
    PubMed     Abstract available

    November 2020
  182. CORTES J
    How to manage CML patients with comorbidities.
    Blood. 2020;136:2507-2512.
    PubMed     Abstract available

  183. NADEU F, Royo R, Clot G, Duran-Ferrer M, et al
    IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
    Blood. 2020 Nov 19. pii: 474211. doi: 10.1182/blood.2020008311.
    PubMed     Abstract available

  184. RAO S
    RUNX1 and inv(16) are frenemies in AML.
    Blood. 2020;136:2361-2362.

  185. PERL AE
    MLL-menin and FLT3 inhibitors team up for AML.
    Blood. 2020;136:2369-2370.

  186. DZAMA MM, Steiner M, Rausch J, Sasca D, et al
    Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Blood. 2020;136:2442-2456.
    PubMed     Abstract available

  187. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available

  188. SURKA C, Jin L, Mbong N, Lu CC, et al
    CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells.
    Blood. 2020 Nov 16. pii: 474181. doi: 10.1182/blood.2020008676.
    PubMed     Abstract available

  189. WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
    Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
    Blood. 2020;136:2319-2333.
    PubMed     Abstract available

  190. SHARMA S, Pavlasova G, Seda V, Cerna K, et al
    miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
    Blood. 2020 Nov 10. pii: 474127. doi: 10.1182/blood.2020005627.
    PubMed     Abstract available

  191. CHEVILLON F, Clappier E, Arfeuille C, Cayuela JM, et al
    Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia.
    Blood. 2020 Nov 10. pii: 474130. doi: 10.1182/blood.2020007782.
    PubMed     Abstract available

  192. HANEKAMP D, Ngai LL, Janssen JJ, van de Loosdrecht AA, et al
    Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.
    Blood. 2020 Nov 10. pii: 474126. doi: 10.1182/blood.2020007150.

  193. RIBERA JM, Morgades M, Ciudad J, Montesinos P, et al
    Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
    Blood. 2020 Nov 4. pii: 474081. doi: 10.1182/blood.2020007311.
    PubMed     Abstract available

  194. GOTTSCHALK HOJFELDT S, Grell K, Abrahamsson J, Lund B, et al
    Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia.
    Blood. 2020 Nov 4. pii: 474076. doi: 10.1182/blood.2020006583.
    PubMed     Abstract available

    October 2020
  195. ROY A
    A "gut feeling" about precursor B-ALL.
    Blood. 2020;136:1995-1996.

  196. YANG W, Devidas M, Liu Y, Smith C, et al
    Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations.
    Blood. 2020 Oct 26. pii: 469753. doi: 10.1182/blood.2020008471.

    Rerouting DOT1L inhibitors in leukemia.
    Blood. 2020;136:1900-1901.

    Cost-effectiveness targeting CLL.
    Blood. 2020;136:1896-1898.

  199. PERNER F, Gadrey JY, Xiong Y, Hatton C, et al
    Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.
    Blood. 2020;136:1983-1988.

  200. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available

  201. BRIVIO E, Locatelli F, Lopez-Yurda M, Malone A, et al
    A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Blood. 2020 Oct 16. pii: 469618. doi: 10.1182/blood.2020007848.
    PubMed     Abstract available

  202. PASSARO D
    Myeloid cells hold the master key for T-ALL spread.
    Blood. 2020;136:1799-1800.

  203. INABA H, Pui CH
    Intensive but tender care for infant ALL.
    Blood. 2020;136:1797-1798.

  204. DUPLOYEZ N, Jamrog LA, Fregona V, Hamelle C, et al
    Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.
    Blood. 2020 Oct 9. pii: 464429. doi: 10.1182/blood.2020005756.
    PubMed     Abstract available

  205. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy of pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction.
    Blood. 2020 Oct 8. pii: 464272. doi: 10.1182/blood.2020007977.
    PubMed     Abstract available

  206. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow.
    Blood. 2020 Oct 7. pii: 464167. doi: 10.1182/blood.2020006219.

  207. NIEMANN CU, Levin MD, Dubois J, Kersting S, et al
    Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2020 Oct 7. pii: 464169. doi: 10.1182/blood.2020008608.

  208. BARKSDALE B, Leith CP
    CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
    Blood. 2020;136:1698.

    HHEX expression drives AML development.
    Blood. 2020;136:1575-1576.

  210. TAKEDA R, Asada S, Park SJ, Yokoyama A, et al
    HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Blood. 2020;136:1670-1684.
    PubMed     Abstract available

    September 2020
  211. WANG W, Thakral B
    CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?
    Blood. 2020;136:1565.

  212. THANGAVELU G, Wang C, Loschi M, Saha A, et al
    Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses.
    Blood. 2020 Sep 24. pii: 463979. doi: 10.1182/blood.2020005628.
    PubMed     Abstract available

  213. TAYLOR J, Mi X, North K, Binder M, et al
    Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
    Blood. 2020;136:1477-1486.
    PubMed     Abstract available

  214. PEPPER M, Tan B
    Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia.
    Blood. 2020;136:1467.

  215. Enshaei A, O'Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.
    Blood. 2020;136:1468.

  216. PINA-OVIEDO S, Thanendrarajan S
    Meningeosis myelomatosis.
    Blood. 2020;136:1466.

  217. STENGER D, Stief TA, Kaeuferle T, Willier S, et al
    Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Blood. 2020;136:1407-1418.
    PubMed     Abstract available

  218. UY GL, Aldoss I, Foster MC, Sayre PH, et al
    Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.
    Blood. 2020 Sep 14. pii: 463757. doi: 10.1182/blood.2020007732.
    PubMed     Abstract available

  219. ZHEN T, Cao Y, Ren G, Zhao L, et al
    RUNX1 and CBFbeta-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Blood. 2020 Sep 14. pii: 463758. doi: 10.1182/blood.2020007747.
    PubMed     Abstract available

  220. VICENTE DUENAS C, Janssen S, Oldenburg M, Auer F, et al
    An intact gut microbiome protects genetically predisposed mice against leukemia.
    Blood. 2020 Sep 10. pii: 463729. doi: 10.1182/blood.2019004381.
    PubMed     Abstract available

  221. KAWABATA KC, Zong H, Meydan C, Wyman S, et al
    BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Blood. 2020 Sep 10. pii: 463728. doi: 10.1182/blood.2019001745.
    PubMed     Abstract available

  222. WILL B
    No keto for AML stem cells!
    Blood. 2020;136:1219-1221.

    Detonating T-ALL.
    Blood. 2020;136:1218-1219.

  224. YUSUF RZ, Saez B, Sharda A, van Gastel N, et al
    Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
    Blood. 2020;136:1303-1316.
    PubMed     Abstract available

  225. SONG L, Yu B, Yang Y, Liang J, et al
    Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.
    Blood. 2020 Sep 8. pii: 463712. doi: 10.1182/blood.2020005622.
    PubMed     Abstract available

    When CLL meets COVID-19.
    Blood. 2020;136:1115-1116.

  227. MATO AR, Roeker LE, Lamanna N, Allan JN, et al
    Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Blood. 2020;136:1134-1143.
    PubMed     Abstract available

  228. FULTANG L, Booth S, Yogev O, Martins da Costa B, et al
    Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.
    Blood. 2020;136:1155-1160.
    PubMed     Abstract available

  229. TEACHEY DT, Hunger SP, Loh ML
    Optimizing Therapy in the Modern Age: Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia.
    Blood. 2020 Sep 2. pii: 463610. doi: 10.1182/blood.2020007702.
    PubMed     Abstract available

  230. SHANMUGANATHAN N, Pagani IS, Ross DM, Park S, et al
    Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463598. doi: 10.1182/blood.2020005514.
    PubMed     Abstract available

  231. XIAO W, Chan A, Waarts MR, Mishra T, et al
    Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463602. doi: 10.1182/blood.2020007897.
    PubMed     Abstract available

  232. FENWARTH L, Thomas X, de Botton S, Duployez N, et al
    A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.
    Blood. 2020 Sep 1. pii: 463599. doi: 10.1182/blood.2020005524.
    PubMed     Abstract available

    August 2020
  233. TAN Y, Wang X, Song H, Zhang Y, et al
    A PML/RARalpha direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
    Blood. 2020 Aug 27. pii: 463523. doi: 10.1182/blood.2020005698.
    PubMed     Abstract available

  234. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.

  235. LUEDKE C, Rein L
    Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.
    Blood. 2020;136:1113.

  236. DEWOLF S, Tallman MS
    How I treat relapsed or refractory AML.
    Blood. 2020;136:1023-1032.
    PubMed     Abstract available

  237. FANG H, Xu J
    Blastoid plasma cell leukemia mimicking acute leukemia.
    Blood. 2020;136:1012.

  238. LIU H
    NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy.
    Blood. 2020;136:1011.

  239. MALINGE S
    SNAIL trail in myeloid malignancies.
    Blood. 2020;136:920-921.

    Deletions in BCP-ALL result in a TAD more FLT3.
    Blood. 2020;136:919-920.

  241. CARMICHAEL CL, Wang J, Nguyen T, Kolawole O, et al
    The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
    Blood. 2020;136:957-973.
    PubMed     Abstract available

  242. ALBERTI-SERVERA L, Demeyer S, Govaerts I, Swings T, et al
    Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
    Blood. 2020 Aug 18. pii: 463329. doi: 10.1182/blood.2020006996.
    PubMed     Abstract available

  243. JOLLY CJ, Pimanda JE
    Titans awake: HMAs for virus-driven ATL.
    Blood. 2020;136:777-779.

  244. WATANABE T, Yamashita S, Ureshino H, Kamachi K, et al
    Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
    Blood. 2020;136:871-884.
    PubMed     Abstract available

    Erythroleukemia: all roads lead to GATA1?
    Blood. 2020;136:648-649.

  246. FAGNAN A, Bagger FO, Pique-Borras MR, Ignacimouttou C, et al
    Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
    Blood. 2020;136:698-714.
    PubMed     Abstract available

  247. GARCIA-MANERO G, Griffiths EA, Steensma DP, Roboz GJ, et al
    Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
    Blood. 2020;136:674-683.
    PubMed     Abstract available

  248. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and re-sensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2020 Aug 5. pii: 461709. doi: 10.1182/blood.2020005712.
    PubMed     Abstract available

    July 2020
  249. YOSHINO S, Yokoyama T, Sunami Y, Takahara T, et al
    Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
    Blood. 2020 Jul 30. pii: 461620. doi: 10.1182/blood.2019004586.
    PubMed     Abstract available

  250. CARROLL M
    A common protein target for an uncommon subtype of AML.
    Blood. 2020;136:377-378.

  251. BEAUMONT AL, Suner L
    Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement.
    Blood. 2020;136:520.

  252. ASSAF N, Terre C
    Double translocation or gene insertion? A BCR/ABL1 fusion in Philadelphia-negative CML.
    Blood. 2020;136:521.

  253. SAAD M, Loh KP, Tooze JA, Pardee TS, et al
    Geriatric assessment and survival among older adults receiving post-remission therapy for acute myeloid leukemia.
    Blood. 2020 Jul 22. pii: 461543. doi: 10.1182/blood.2020005498.

  254. NISHII R, Baskin-Doerfler R, Yang W, Oak N, et al
    Molecular Basis of ETV6-Mediated Predisposition to Childhood Acute Lymphoblastic Leukemia.
    Blood. 2020 Jul 21. pii: 461432. doi: 10.1182/blood.2020006164.
    PubMed     Abstract available

  255. BRADY SW, Ma X, Zhou BS, Pui CH, et al
    Response to "Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?"
    Blood. 2020 Jul 20. pii: 461427. doi: 10.1182/blood.2020008107.

  256. BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
    Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
    Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
    PubMed     Abstract available

  257. PIVA E, Tosato F
    Promyelocytic leukemia with basophil-like granules.
    Blood. 2020;136:372.

  258. STOCK W
    Thrombosis in ALL: a risk without clear mitigation.
    Blood. 2020;136:264-265.

  259. MOLINA O, Vinyoles M, Granada I, Roca-Ho H, et al
    Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL.
    Blood. 2020;136:313-327.
    PubMed     Abstract available

  260. MUJAHED H, Miliara S, Neddermeyer A, Bengtzen S, et al
    AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
    Blood. 2020;136:339-352.
    PubMed     Abstract available

  261. TSURUTA Y, Karube K
    Hodgkin and Reed-Sternberg-like cells infected with human T-cell leukemia virus type 1.
    Blood. 2020;136:257.

  262. Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.
    Blood. 2020;136:259.

  263. LYAPICHEV KA, Jelloul FZ
    Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma.
    Blood. 2020;136:258.

  264. TOMIZAWA D, Miyamura T, Imamura T, Watanabe T, et al
    A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
    Blood. 2020 Jul 7. pii: 461277. doi: 10.1182/blood.2019004741.
    PubMed     Abstract available

  265. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.

    Occupy BTK: the key to controlling CLL.
    Blood. 2020;136:4-6.

  267. LICHT JD
    Oncogenesis by E2A-PBX1 in ALL: RUNX and more.
    Blood. 2020;136:3-4.

  268. KHAN DH, Mullokandov M, Wu Y, Voisin V, et al
    Mitochondrial carrier homolog 2 is necessary for AML survival.
    Blood. 2020;136:81-92.
    PubMed     Abstract available

  269. SUN C, Nierman P, Kendall EK, Cheung J, et al
    Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Blood. 2020;136:93-105.
    PubMed     Abstract available

  270. FALINI B, Brunetti L, Sportoletti P, Martelli MP, et al
    NPM1-mutated acute myeloid leukemia: from bench to bedside.
    Blood. 2020 Jul 1. pii: 461241. doi: 10.1182/blood.2019004226.
    PubMed     Abstract available

    June 2020
  271. GAYNON PS, Orgel E, Ji L
    Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?
    Blood. 2020 Jun 30. pii: 461230. doi: 10.1182/blood.2020005258.

  272. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.
    Blood. 2020 Jun 29. pii: 461224. doi: 10.1182/blood.2020006374.
    PubMed     Abstract available

  273. HUNGER SP, Raetz E
    How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population.
    Blood. 2020 Jun 26. pii: 461194. doi: 10.1182/blood.2019004043.
    PubMed     Abstract available

  274. GIOTOPOULOS G, Huntly BJP
    CML: new tools to answer old questions.
    Blood. 2020;135:2327-2328.

  275. STANKOVIC T, Kwok M
    Genetics in the era of targeted CLL therapy.
    Blood. 2020;135:2333-2334.

  276. GEYER HL, Gazelka H, Mesa R
    How I treat pain in hematologic malignancies safely with opioid therapy.
    Blood. 2020;135:2354-2364.
    PubMed     Abstract available

  277. TAUSCH E, Schneider C, Robrecht S, Zhang C, et al
    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Blood. 2020;135:2402-2412.
    PubMed     Abstract available

  278. MATSUMURA T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, et al
    Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
    Blood. 2020 Jun 23. pii: 461100. doi: 10.1182/blood.2019004292.
    PubMed     Abstract available

  279. CUNEO A, Scarfo L, Reda G, Varettoni M, et al
    Blood. 2020 Jun 19. pii: 461059. doi: 10.1182/blood.2020006854.

  280. RAFFEL S, Klimmeck D, Falcone M, Demir A, et al
    Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells.
    Blood. 2020 Jun 18. pii: 461031. doi: 10.1182/blood.2019003654.
    PubMed     Abstract available

  281. Setd2 deficiency accelerated MDS-related leukemia.
    Blood. 2020;135:2326.

  282. CRUZ HERNANDEZ D, Metzner M, de Groot AP, Usukhbayar B, et al
    Sensitive, Rapid Diagnostic Test For Transient Abnormal Myelopoiesis and Myeloid Leukemia of Down Syndrome.
    Blood. 2020 Jun 18. pii: 461036. doi: 10.1182/blood.2020005610.

  283. BROWN JR
    Inverting the BTK-BCL2 order.
    Blood. 2020;135:2205-2207.

  284. GRANTS JM, Wegrzyn J, Hui T, O'Neill K, et al
    Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice.
    Blood. 2020;135:2235-2251.
    PubMed     Abstract available

  285. LIN VS, Lew TE, Handunnetti SM, Blombery P, et al
    BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Blood. 2020;135:2266-2270.
    PubMed     Abstract available

  286. CHEN BY, Song J, Hu CL, Chen SB, et al
    SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Blood. 2020;135:2271-2285.
    PubMed     Abstract available

    ON TRacK towards novel targets in leukemia.
    Blood. 2020;135:2117-2119.

  288. LOWENBERG B, Huls G
    The long road: improving outcome in elderly "unfit" AML?
    Blood. 2020;135:2114-2115.

  289. LUCAS F, Larkin K, Gregory CT, Orwick S, et al
    Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Blood. 2020;135:2192-2195.

  290. WEI AH, Montesinos P, Ivanov V, DiNardo CD, et al
    Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Blood. 2020;135:2137-2145.
    PubMed     Abstract available

  291. DIRAL E, Mori S, Antolini L, Abruzzese E, et al
    Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation.
    Blood. 2020 Jun 9. pii: 460734. doi: 10.1182/blood.2019004371.

  292. PATEL K, Isufi I, Kothari S, Davidoff AJ, et al
    Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia.
    Blood. 2020 Jun 9. pii: 460741. doi: 10.1182/blood.2020004922.
    PubMed     Abstract available

  293. Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.
    Blood. 2020;135:2111.

  294. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.

  295. ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
    Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
    Blood. 2020 Jun 4. pii: 460669. doi: 10.1182/blood.2019004583.
    PubMed     Abstract available

  296. AN J, Ko M
    Decoding ribosomes to keep growing (in AML).
    Blood. 2020;135:2015-2016.

  297. SAINI NY, Marin D, Ledesma C, Delgado R, et al
    Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2020 Jun 3. pii: 460671. doi: 10.1182/blood.2019004685.

  298. TRAN QUANG C, Zaniboni B, Humeau R, Lengline E, et al
    Preclinical Efficacy of Humanized, non-FcgammaR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2020 Jun 1. pii: 460600. doi: 10.1182/blood.2019003801.
    PubMed     Abstract available

    May 2020

  299. Passet M, Boissel N, Sigaux F, et al; Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284.
    Blood. 2020;135:2011.

  300. NEGRETE D, Huang Q
    A striking case of iatrogenic granulocytic nuclear abnormality in the bone marrow.
    Blood. 2020;135:2010.

  301. SCHRATZ KE, Haley L, Danoff SK, Blackford AL, et al
    Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
    Blood. 2020;135:1946-1956.
    PubMed     Abstract available

  302. ABDO C, Thonier F, Simonin M, Kaltenbach S, et al
    Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
    Blood. 2020 May 21. pii: 456040. doi: 10.1182/blood.2020005613.

  303. SUNG PJ, Babushok DV
    Born to RUNX1.
    Blood. 2020;135:1824-1825.

  304. TAM CS, Seymour JF
    A predictive tool for early-stage CLL.
    Blood. 2020;135:1820-1821.

  305. SIMON L, Spinella JF, Yao CY, Lavallee VP, et al
    High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
    Blood. 2020;135:1882-1886.
    PubMed     Abstract available

  306. MENSSEN AJ, Walter MJ
    Genetics of Progression from MDS to Secondary Leukemia.
    Blood. 2020 May 19. pii: 456027. doi: 10.1182/blood.2019000942.
    PubMed     Abstract available

  307. SUN L, Babushok DV
    Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood. 2020 May 19. pii: 456026. doi: 10.1182/blood.2019000940.
    PubMed     Abstract available

  308. DUNBAR A, Rampal R, Levine RL
    Secondary leukemia to myeloproliferative neoplasms.
    Blood. 2020 May 19. pii: 456028. doi: 10.1182/blood.2019000943.
    PubMed     Abstract available

  309. SOULIER J
    Introduction to a review series on secondary leukemia.
    Blood. 2020 May 19. pii: 456030. doi: 10.1182/blood.2019004171.

  310. SCOTT HS, Hahn CN, Brown AL
    Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
    Blood. 2020 May 19. pii: 456025. doi: 10.1182/blood.2019000937.
    PubMed     Abstract available

  311. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.

  312. GEBRU MT, Atkinson JM, Young M, Zhang L, et al
    Glucocorticoids enhance the anti-leukemic activity of FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
    Blood. 2020 May 12. pii: 455305. doi: 10.1182/blood.2019003124.
    PubMed     Abstract available

  313. SONG C, Ge Z, Ding Y, Tan BH, et al
    IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia.
    Blood. 2020 May 12. pii: 455304. doi: 10.1182/blood.2019002655.
    PubMed     Abstract available

  314. TULSTRUP M, Moriyama T, Jiang C, Grosjean M, et al
    Effects of germline variants in DHFR and FPGS on methotrexate metabolism and relapse of leukemia.
    Blood. 2020 May 11. pii: 455060. doi: 10.1182/blood.2020005064.
    PubMed     Abstract available

  315. YANG M, Safavi S, Woodward EL, Duployez N, et al
    13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
    Blood. 2020 May 8. pii: 454973. doi: 10.1182/blood.2019004684.
    PubMed     Abstract available

  316. KATER AP, Melenhorst JJ
    CAR-T and ibrutinib vs CLL: sequential or simultaneous?
    Blood. 2020;135:1611-1612.

  317. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.

  318. RONNER L, Podoltsev N, Gotlib J, Heaney ML, et al
    Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
    Blood. 2020;135:1696-1703.
    PubMed     Abstract available

  319. GAUTHIER J, Hirayama AV, Purushe J, Hay KA, et al
    Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Blood. 2020;135:1650-1660.
    PubMed     Abstract available

    April 2020
  320. DE DOMINICI M, Porazzi P, Xiao Y, Chao A, et al
    Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
    Blood. 2020;135:1560-1573.
    PubMed     Abstract available

  321. SCHMOELLERL J, Barbosa IAM, Eder T, Brandstoetter T, et al
    CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia.
    Blood. 2020 Apr 28. pii: 454667. doi: 10.1182/blood.2019003267.
    PubMed     Abstract available

  322. LONG J, Jia MY, Fang WY, Chen XJ, et al
    FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Blood. 2020;135:1472-1483.
    PubMed     Abstract available

  323. ENSHAEI A, O'Connor D, Bartram J, Hancock J, et al
    A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
    Blood. 2020;135:1438-1446.
    PubMed     Abstract available

  324. KRAUSE DS
    The Fox(o) and the HDAC.
    Blood. 2020;135:1416-1417.

    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.

  326. COOK LBM, Rowan AG
    CD28 fusions: an opportunity for young ATL?
    Blood. 2020;135:1415-1416.

  327. LIU H, Hu S
    Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation.
    Blood. 2020;135:1506.

  328. WIERDA WG, Tambaro FP
    How I manage CLL with venetoclax-based treatments.
    Blood. 2020;135:1421-1427.
    PubMed     Abstract available

  329. CLESHAM K, Rao V, Bartram J, Ancliff P, et al
    Blinatumomab for infant acute lymphoblastic leukemia.
    Blood. 2020;135:1501-1504.

  330. YOSHIDA N, Shigemori K, Donaldson N, Trevisani C, et al
    Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.
    Blood. 2020;135:1467-1471.
    PubMed     Abstract available

  331. ORVAIN C, Balsat M, Tavernier E, Marolleau JP, et al
    Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study.
    Blood. 2020 Apr 22. pii: 454452. doi: 10.1182/blood.2020004919.
    PubMed     Abstract available

  332. MARRA A, Martino G
    Placental myeloid sarcoma.
    Blood. 2020;135:1410.

  333. HAROCHE J, Cohen-Aubart F, Amoura Z
    Erdheim-Chester disease.
    Blood. 2020;135:1311-1318.
    PubMed     Abstract available

  334. SCHETELIG J, Baldauf H, Heidenreich F, Massalski C, et al
    External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Blood. 2020;135:1386-1395.
    PubMed     Abstract available

  335. PATNAIK MM, Sallman DA, Mangaonkar A, Heuer R, et al
    Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML).
    Blood. 2020 Apr 15. pii: 454390. doi: 10.1182/blood.2019004352.

  336. PI WC, Wang J, Shimada M, Lin JW, et al
    E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
    Blood. 2020 Apr 10. pii: 454360. doi: 10.1182/blood.2019003312.
    PubMed     Abstract available

  337. HSU A, Freeman N
    The fertile field of "isomopic" immune dysregulation as a nidus for lymphoproliferative disorders.
    Blood. 2020;135:1303.

  338. SAENZ DT, Fiskus W, Mill CP, Perera D, et al
    Mechanistic basis and efficacy of targeting the beta-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
    Blood. 2020;135:1255-1269.
    PubMed     Abstract available

  339. CONDOLUCI A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, et al
    International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.
    Blood. 2020 Apr 8. pii: 454292. doi: 10.1182/blood.2019003453.
    PubMed     Abstract available

  340. LIN H, Rothe K, Chen M, Wu A, et al
    The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML.
    Blood. 2020 Apr 8. pii: 454304. doi: 10.1182/blood.2019003636.
    PubMed     Abstract available

  341. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.

  342. GHANNAM JY, Xu X, Maric I, Dillon L, et al
    Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.
    Blood. 2020;135:1185-1188.

    March 2020
  343. OTTEMA S, Mulet-Lazaro R, Beverloo HB, Erpelinck CAJ, et al
    Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Blood. 2020 Mar 27. pii: 454178. doi: 10.1182/blood.2019003701.
    PubMed     Abstract available

  344. GANG EJ, Kim HN, Hsieh YT, Ruan Y, et al
    Integrin alpha6 mediates drug resistance of acute lymphoblastic B-cell leukemia.
    Blood. 2020 Mar 27. pii: 454180. doi: 10.1182/blood.2019001417.
    PubMed     Abstract available

  345. KLEIN E, Bidet A
    MYC and KMT2A multiple extra copies in acute myeloid leukemia.
    Blood. 2020;135:1070.

  346. JINNOUCHI F, Yamauchi T, Yurino A, Nunomura T, et al
    Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.
    Blood. 2020 Mar 23. pii: 452764. doi: 10.1182/blood.2019002194.
    PubMed     Abstract available

  347. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.

  348. HASSERJIAN RP, Steensma DP, Graubert TA, Ebert BL, et al
    Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.
    Blood. 2020 Mar 13. pii: 452698. doi: 10.1182/blood.2019004770.
    PubMed     Abstract available

  349. ABRISQUETA P, Bosch F
    Venetoclax-obinutuzumab: harnessing complexity.
    Blood. 2020;135:788-789.

    BCL-2 inhibition and AML: can we best Darwin?
    Blood. 2020;135:781-782.

  351. DINARDO CD, Tiong IS, Quaglieri A, MacRaild S, et al
    Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    Blood. 2020;135:791-803.
    PubMed     Abstract available

  352. CHONG SJF, Davids MS
    Breaking through BCL-2 inhibition in CLL.
    Blood. 2020;135:709-711.

  353. DAVER N
    A bispecific approach to improving CAR T cells in AML.
    Blood. 2020;135:703-704.

  354. FU CL, Diacovo MJ
    Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen.
    Blood. 2020;135:778.

  355. GOTTSCHALK A, Glauche I, Cicconi S, Clark RE, et al
    Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
    Blood. 2020;135:766-769.

    February 2020
  356. DILLON R, Hills R, Freeman S, Potter N, et al
    Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
    Blood. 2020;135:680-688.
    PubMed     Abstract available

  357. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available

  358. SOVERINI S, Bavaro L, De Benedittis C, Martelli M, et al
    Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Blood. 2020;135:534-541.
    PubMed     Abstract available

  359. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available

  360. KAGOTHO E, Chang H
    CML in megakaryocytic transformation and extramedullary infiltration.
    Blood. 2020;135:514.

  361. STRATI P, Schlette EJ, Solis Soto LM, Duenas DE, et al
    Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
    Blood. 2020;135:510-513.

  362. CIUREA SO, Kongtim P, Varma A, Rondon G, et al
    Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
    Blood. 2020;135:449-452.
    PubMed     Abstract available

  363. KWOK M, Oldreive C, Rawstron AC, Goel A, et al
    Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
    Blood. 2020;135:411-428.
    PubMed     Abstract available

    January 2020
  364. PAN J, Zuo S, Deng B, Xu X, et al
    Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.
    Blood. 2020;135:387-391.

  365. FABRE MA, McKerrell T, Zwiebel M, Vijayabaskar MS, et al
    Concordance for clonal hematopoiesis is limited in elderly twins.
    Blood. 2020;135:269-273.
    PubMed     Abstract available

  366. HANSEN JW, Pedersen DA, Larsen LA, Husby S, et al
    Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality.
    Blood. 2020;135:261-268.
    PubMed     Abstract available

  367. MEYER SE
    MicroRNA immunomodulating therapeutics.
    Blood. 2020;135:155-156.

  368. HALE DA, Krause JR
    Unexpected lymph node finding in a patient with essential thrombocythemia.
    Blood. 2020;135:154.

  369. MORSCIO J, Van Vlierberghe P
    Chemotherapy at the wheel of ALL relapse.
    Blood. 2020;135:4-5.

  370. SWANSON HD, Panetta JC, Barker PJ, Liu Y, et al
    Predicting success of desensitization after pegaspargase allergy.
    Blood. 2020;135:71-75.

  371. LEVIS M, Shi W, Chang K, Laing C, et al
    FLT3 inhibitors added to induction therapy induce deeper remissions.
    Blood. 2020;135:75-78.

  372. WANG N, Hu X, Cao W, Li C, et al
    Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
    Blood. 2020;135:17-27.
    PubMed     Abstract available

    December 2019
  373. GARDNER RA, Ceppi F, Rivers J, Annesley C, et al
    Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Blood. 2019;134:2149-2158.
    PubMed     Abstract available

    October 2019
  374. THANGAVELU G, Du J, Paz KG, Loschi M, et al
    Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.
    Blood. 2019 Oct 15. pii: 387148. doi: 10.1182/blood.2019000032.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.